PMV Pharmaceuticals, Inc. (PMVP)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
PMVP files Annual Report Summary; financial data and guidance unavailable
# ❓ What This Document Is This document is designated as an ARS (Annual Report Summary) for PMV Pharmaceuticals, Inc. (PMVP). ARS filings are typically used to provide a high-level, summary view of a company's annual performance, intended to give investors a quick overview of the most material infor
PMVP shareholders vote on governance, chair transition, and compensation proposals
# 📄 What This Document Is 📜 This document is a Proxy Statement (Form DEF 14A). Think of it as the official rulebook for an annual shareholder meeting. It was filed by PMV Pharmaceuticals, Inc. to ensure every stockholder knows exactly what is going to be voted on and how to participate. The main g
SEC filings
All filings →Insider trades
All insider trades →PMV Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.